Skip to main content
Fig. 3 | Cardiovascular Diabetology

Fig. 3

From: α-Glucosidase inhibitor miglitol attenuates glucose fluctuation, heart rate variability and sympathetic activity in patients with type 2 diabetes and acute coronary syndrome: a multicenter randomized controlled (MACS) study

Fig. 3

Continuous glucose monitoring. a, b Mean variations in 24-h blood glucose measured by a continuous glucose monitoring system in control and miglitol groups. Lines represent mean (solid) ± SD (dotted) of blood glucose levels on Day 1 (black) and Day 2 (blue or red) in a control (n = 17) and b miglitol (n = 13) groups. To see daily variations of glucose levels, we divided time periods into 0700–1800 h (day-time), 1800–0000 h (night-time), and 0000–0700 h (bed-time). Patients took a standard regimen of breakfast, lunch, and supper. The peaks after lunch and supper on Day 2 in the miglitol group (red arrow, Fig. 3b) are indicated by red arrows. c, d Levels of mean glucose, minimum (min) glucose, maximum (max) glucose, ∆glucose, SD glucose, and MAGE during 24-h in the control and miglitol groups. Boxes represent mean ± SD, and whiskers represent min to max during 24-h on Day 1 and Day 2 in c control (n = 17) and d miglitol (n = 13) groups

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840